Diagnosis of Systemic Lupus Erythematosus

American Family Physician

Volumn 68, Issue 11, 2003, Pages 2179-2186

  Gill, James M ^a   Quisel, Anna M ^b   Rocca, Peter V ^b   Walters, Dene T ^a  

^a CHRISTIANA CARE HEALTH SYSTEM   (United States)

^b Christiana Care Health Services ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; DNA ANTIBODY; DOUBLE STRANDED DNA; SM NUCLEAR ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY TITER; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; HUMAN; LABORATORY DIAGNOSIS; MORBIDITY; MORTALITY; PREVALENCE; PRIMARY MEDICAL CARE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0344630178     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Edworthy SM. Clinical manifestations of systemic lupus erythematosus. In: Ruddy S, Harris ED, Sledge CB, Kelley WN, eds. Kelley's Textbook of rheumatology. 6th ed. Philadelphia: Saunders, 2001:1105-19.
2. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum 1999;42:1785-96.
3. Petri M. Treatment of systemic lupus erythematosus: an update. Am Fam Physician 1998;57:2753-60.
4. Meinao IM, Sato EI, Andrade LE, Ferraz MB, Atra E. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus 1996;5:237-41.
5. Molina JF, McGrath H Jr. Longterm ultraviolet-A1 irradiation therapy in systemic lupus erythematosus. J Rheumatol 1997;24:1072-4.
6. McGrath H, Martinez-Osuna P, Lee FA. Ultraviolet-A1 (340-400 nm) irradiation therapy in systemic lupus erythematosus. Lupus 1996;5:269-74.
7. Dammacco F, Della Casa Alberighi O, Ferraccioli G, Racanelli V, Casatta L, Bartoli E. Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus. Int J Clin Lab Res 2000;30:67-73.
8. Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1999;26:1275-9.
9. Alvarez-Nemegyei J, Cobarrubias-Cobos A, Escalante-Triay F, Sosa-Munoz J, Miranda JM, Jara LJ. Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study. Lupus 1998;7:414-9.
10. Pollak VE, Pirani CL, Kark RM. Effect of large doses of prednisone on the renal lesions of and life span of patients with lupus glomerulonephritis. J Lab Clin Med 1961;57:495-511.
11. Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 1997;29:193-9.
12. Bellomio V, Spindler A, Lucero E, Berman A, Santana M, Moreno C, et al. Systemic lupus erythematosus: mortality and survival in Argentina. A multicenter study. Lupus 2000;9:377-81.
13. Johnson AE, Gordon C, Hobbs FD, Bacon PA. Undiagnosed systemic lupus erythematosus in the community. Lancet 1996;347:367-9.
14. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
15. Lehman TJ. Systemic onset juvenile rheumatoid arthritis. Retrieved March 20, 2003, from http://www.uptodate.com/physicians/rheumatology_toclist.asp.
16. McCarty DJ, Manzi S, Medsger TA Jr, Ramsey-Goldman R, LaPorte RE, Kwoh CK. Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum 1995;38:1260-70.
17. Gourley IS, Cunnane G, Bresnihan B, FitzGerald O, Bell AL. A clinical and serological comparison of familial and non-familial systemic lupus erythematosus in Ireland. Lupus 1996;5:288-93.
18. Grennan DM, Parfitt A, Manolios N, Huang Q, Hyland V, Dunckley H, et al. Family and twin studies in systemic lupus erythematosus. Dis Markers 1997;13:93-8.
19. Gray-McGuire C, Moser KL, Gaffney PM, Kelly J, Yu H, Olson JM, et al. Genome scan of human systemic lupus erythematosus by regression modeling: evidence of linkage and epistasis at 4p16-15.2. Am J Hum Genet 2000;67:1460-9.
20. Schur PH. General symptomatology and diagnosis of systemic lupus erythematosus in adults. Retrieved March 20, 2003, from http://www.uptodate.com/physicians/rheumatology_toclist.asp.
21. Gilboe IM, Husby G. Application of the 1982 revised criteria for the classification of systemic lupus erythematosus on a cohort of 346 Norwegian patients with connective tissue disease. Scand J Rheumatol 1999;28:81-7.
22. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15.
23. Jonsson H, Nived O, Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine [Baltimore] 1989;68:141-50.
24. Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest J Jr. Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol 1999;26:2363-8.
25. Singh S, Kumar L, Khetarpal R, Aggarwal P, Marwaha RK, Minz RW, et al. Clinical and immunological profile of SLE: some unusual features. Indian Pediatr 1997;34:979-86.
26. Marini R, Costallat LT. Young age at onset, renal involvement, and atrial hypertension are of adverse prognostic significance in juvenile systemic lupus erythematosus. Rev Rhum Engl Ed 1999;66:303-9.
27. Rood MJ, ten Cate R, van Suijlekom-Smit LW, den Ouden EJ, Ouwerkerk FE, Breedveld FC, et al. Childhood-onset systemic lupus erythematosus: clinical presentation and prognosis in 31 patients. Scand J Rheumatol 1999;28:222-6.
28. Carreno L, Lopez-Longo FJ, Monteagudo I, Rodriguez-Mahou M, Bascones M, Gonzalez CM, et al. Immunological and clinical differences between juvenile and adult onset of systemic lupus erythematosus. Lupus 1999;8:287-92.
29. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison. J Rheumatol 2000;27:373-6.
30. Rivest C, Lew RA, Welsing PM, Sangha O, Wright EA, Roberts WN, et al. Association between clinical factors, socioeconomic status, and organ damage in recent onset systemic lupus erythematosus. J Rheumatol 2000;27:680-4.
31. Schur PH. Overview of the therapy and prognosis of systemic lupus erythematosus in adults. Retrieved March 20, 2003, from http://www.uptodate.com/physicians/rheumatology_toclist.asp.
32. Stahl-Hallengren C, Jonsen A, Nived O, Sturfelt G. Incidence studies of systemic lupus erythematosus in southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 2000;27:685-91.
33. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine [Baltimore] 1999;78:167-75.
34. Mok CC, Lau CS, Chan TM, Wong RW. Clinical characteristics and outcome of southern Chinese males with systemic lupus erythematosus. Lupus 1999;8:188-96.
35. Koh ET, Seow A, Leong KH, Chng HH. SLE mortality in an oriental population. Lupus 1997;6:27-31.
36. Jacobsen S, Petersen J, Ullman S, Junker P, Voss A, Rasmussen JM, et al. A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic value. Clin Rheumatol 1998;17:478-84.
37. Blanco FJ, Gomez-Reino JJ, de la Mata J, Corrales A, Rodriguez-Varverde V, Rosas JC, et al. Survival analysis of 306 European Spanish patients with systemic lupus erythematosus. Lupus 1998;7:159-63.
38. Uramoto KM, Michet CJ Jr, Thumboo J, Sunku J, O'Fallon WM, Gabriel SE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999;42:46-50.
39. Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT. Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol 1997;24:1061-5.
40. Ward MM. Hospital experience and expected mortality in patients with systemic lupus erythematosus: a hospital level analysis. J Rheumatol 2000;27:2146-51.
41. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
42. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [Letter]. Arthritis Rheum 1997;40:1725.
43. Ferraz MB, Gordenberg J, Hilario MO, Bastos WA, Oliveira SK, Azevedo EC, et al. Evaluation of the 1982 ARA lupus criteria data set in pediatric patients. Committees of Pediatric Rheumatology of the Brazilian Society of Pediatrics and the Brazilian Society of Rheumatology. Clin Exp Rheumatol 1994;12:83-7.
44. Malleson PN, Sailer M, Mackinnon MJ. Usefulness of antinuclear antibody testing to screen for rheumatic diseases. Arch Dis Child 1997;77:299-304.
45. Guidelines for the initial evaluation of the adult patient with acute musculoskeletal symptoms. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996;39:1-8.
46. Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med 2000;124:71-81.